Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ
Home Search Quick Search Advanced Fulltext Browse Collections Persons My eDoc Session History Login Name: Password: Documentation Help Support Wiki Direct access to document ID:	Institute: MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut)     Collection: Yearbook 2016     Display Documents ID: 723936.0, MPI für Herz- und Lungenforschung (W. G. Kerckhoff Institut) / Yearbook 2016 [Medical treatment of pulmonary hypertension: what's new?] Authors: Richter, M. J.; Gall, H.; Tello, K.; Sommer, N.; Seeger, W.; Grimminger, F.; Ghofrani, H. A. Date of Publication (YYYY-MM-DD): 2015-05 Title of Journal: Internist (Berl) Volume: 56 Issue / Number: 5 Start Page: 573 End Page: 582 Audience: Not Specified Abstract / Description: Pulmonary hypertension (PH) is a chronic progressive disease of the pulmonary circulation of multifactorial causes. The current diagnostic classification of PH distinguishes five main groups, which have as a common feature an increased pulmonary arterial pressure and pulmonary resistance. The classification differentiates pulmonary arterial hypertension (PAH), PH due to left heart disease, PH in lung diseases and/or hypoxia, chronic thromboembolic pulmonary hypertension (CTEPH), and PH with unclear/multifactorial mechanisms. Recent advances in basic research with the approval of new drugs and the establishment of therapeutic strategies, mainly in PAH and CTEPH, require a differentiated view of the disease, a careful diagnosis and initiation of therapy, and regular follow-ups. In this article, we provide an overview of the complex drug therapy currently available for PAH patients. Free Keywords: Antihypertensive Agents/*administration & dosage; Endothelin Receptor Antagonists/*administration & dosage; Evidence-Based Medicine; Guanylate Cyclase; Humans; Hypertension, Pulmonary/diagnosis/*drug therapy; Phosphodiesterase 5 Inhibitors/*administration & dosage; Prostaglandins/*administration & dosage; Receptors, Cytoplasmic and Nuclear/*agonists; Treatment Outcome External Publication Status: published Document Type: Article Communicated by: n.n. Affiliations: MPI für physiologische und klinische Forschung Identifiers: ISSN:1432-1289 (Electronic) 0020-9554 (Linking) %R 10.1007/s00108-015-3693-0 %(Medikamentose Therapie der pulmonalen Hypertonie: Was ist neu? URL:http://www.ncbi.nlm.nih.gov/pubmed/25924799 The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.